Pancreatic cancer pill trial, Digimart Global (United Kingdom): A daily pill is being described by some experts as the biggest breakthrough in pancreatic cancer treatment for decades, after early trial results suggested it can shrink and, in some cases, eliminate tumours. The drug, daraxonrasib, was given alongside chemotherapy to patients with one of the deadliest and hardest-to-treat cancers.
In the early trial, tumours stopped growing in almost all of the 61 participants who had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body. Just over 60% of patients saw their tumours shrink or disappear, and for around 8% of patients, or one in 12, the cancer became undetectable on CT scans.
Doctors stress that these findings do not mean the disease has been cured. Dr Wungki Park, from Memorial Sloan Kettering Cancer Center in the US and involved in the trial, said the response rates and a near doubling in the duration of disease control were encouraging, and may eventually translate into longer survival.
Participants were followed for around a year and a half on average, and some did not see their cancer return during that time.
Cancer Research UK described the results as “the biggest leap forward in decades” for patients. Its Dr Sam Godfrey said progress in pancreatic cancer was long overdue, but warned that a lack of visible cancer on scans does not necessarily mean a patient is cancer-free until more time has passed.
Longer studies are needed to establish whether any of these cancers can go into remission, and for how long.
Pancreatic cancer has the lowest survival rate of all common cancers in the UK, and chemotherapy often shrinks tumours only a little before they grow back. Most patients with advanced disease survive months rather than years.
Professor Elena Garralda, chair of the European cancer conference where the work is being presented, said the combined treatment could potentially improve overall survival and the time before tumours begin to grow again.
Daraxonrasib is a KRAS inhibitor that has already been approved in the US. It targets RAS mutations found in most pancreatic cancers, which drive tumour growth.
Similar mutations occur in dozens of other cancers, including lung and ovarian, so the drug may eventually help other patients, although that remains to be tested. According to Cancer Research UK, there are around 11,500 diagnoses of pancreatic cancer in Britain each year and around 10,200 deaths.














